Kohjin Bio Co Financial Leverage

What does Kohjin Bio Co do? Kohjin Bio Co Ltd generates revenue through three business segments. The Tissue Culture segment sells serum-free media for regenerative medicine and immunotherapy research, targeting research institutions and biotech companies. The Microbiology segment offers pathogen testing media for clinical, food, and pharmaceutical quality control, purchased by hospitals, food producers, and cosmetics manufacturers. The Cell Processing segment provides contract cell processing services to medical institutions under the Regenerative Medicine Safety Act, with facilities approved for manufacturing specified cell products. Revenue comes from direct sales of media products and service contracts for cell processing operations. The company's products include bacterial testing media, in vitro diagnostic drugs, and cell culture media, all sold under its own brand. Medical institutions, research organizations, and quality control departments in food and pharmaceutical industries are the primary buyers. The Microbiology segment serves clinical laboratories and food safety testing facilities, while the Tissue Culture segment caters to regenerative medicine research centers. Cell Processing services are contracted by hospitals and clinics requiring specialized cell manufacturing under regulatory compliance. Kohjin Bio's business model relies on selling specialized media for laboratory and medical applications, with recurring revenue from long-term contracts in cell processing. The Microbiology segment's products are used in routine pathogen testing, ensuring steady demand from healthcare and food sectors. The Tissue Culture segment's serum-free media support emerging therapies, attracting biotech firms seeking advanced research tools. Cell Processing services are driven by Japan's expanding regenerative medicine market, where medical institutions outsource cell manufacturing to compliant facilities. Kohjin Bio Co is one of the most popular companies on Eulerpool.